126645-75-8 Usage
General Description
(4-Benzyl-morpholin-2-ylmethyl)-methyl-amine is a chemical compound with the formula C17H24N2O. It is a derivative of morpholine and has a benzyl group attached to the morpholine ring. (4-BENZYL-MORPHOLIN-2-YLMETHYL)-METHYL-AMINE is used in organic synthesis as a reagent for the preparation of various organic compounds. It has also been studied for its potential pharmacological properties, particularly as an antipsychotic and antidepressant agent. Additionally, it has been investigated for its potential use as a ligand in coordination chemistry and as a building block in the synthesis of heterocyclic compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 126645-75-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,6,6,4 and 5 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 126645-75:
(8*1)+(7*2)+(6*6)+(5*6)+(4*4)+(3*5)+(2*7)+(1*5)=138
138 % 10 = 8
So 126645-75-8 is a valid CAS Registry Number.
InChI:InChI=1/C13H20N2O/c1-14-9-13-11-15(7-8-16-13)10-12-5-3-2-4-6-12/h2-6,13-14H,7-11H2,1H3
126645-75-8Relevant articles and documents
Combination therapy with CHK1 inhibitors
-
, (2008/06/13)
Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents.
BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
-
Page 326, (2008/06/13)
Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.